venerdì, 26 novembre 2021
20 Gennaio 2017

FDA Approves Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma

The U.S. Food and Drug Administration (FDA) today approved ibrutinib for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti–CD20-based therapy. Accelerated approval was granted for this indication based on overall response rate (ORR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Ibrutinib … (leggi tutto)